Ultragenyx wins gene-therapy approval but Angelman trial fails
Q2 revenue jump and narrower loss Ultragenyx's second-quarter loss narrowed to 90 cents a share and revenue rose 28% to a record $214 million, beating expectations. The company kept its full-year revenue guidance. This supports the stock by showing the commercial business is growing and funding pipeline work.
It shows the underlying business is healthy, which matters for valuation even after the trial failure.
FDA approves Genglycos gene therapy The FDA granted accelerated approval to Genglycos (DTX401) for glycogen storage disease type Ia, the first gene therapy for this rare disorder. It has a $2.7 million list price and should launch within 30-60 days. This adds a new commercial product, though the patient pool is tiny (1,500-2,500 in the U.S.).
A new approved product is a major positive driver for future revenue.
96-week data reinforces Genglycos benefit Published 96-week data showed Genglycos cut daily cornstarch intake by 61% and helped many patients eliminate nighttime doses, with a tolerable safety profile. This strengthens the case for the newly approved therapy and supports doctor and payer confidence.
It backs up the approval with longer-term evidence, helping adoption.
Angelman syndrome trial fails, stock plunges The Phase 3 Aspire study of apazunersen (GTX-102) missed its primary and key secondary goals, wiping 43-46% off the stock to an all-time low. Analysts downgraded the stock, citing a complete miss. The company will cut expenses and review the program, but the commercial business offers some valuation floor.
This is the biggest new negative event, directly causing the stock's collapse.